@FierceBiotech: NuPathe jumps on FDA's OK for migraine drug. News | Follow @FierceBiotech
@JohnCFierce: VC ends '12 on a high note, outlook ranges from tough to terrific. More | Follow @JohnCFierce
@RyanMFierce: Does anyone know how much total funding (VC, corp., foundation) went into biotech? Still, $800M off in 2012 from '11 on the VC front. Yikes. | Follow @RyanMFierce
> Trius Therapeutics ($TSRX), which has a lead antibiotic against MRSA in Phase III development, has priced shares for a public offering worth $29.9 million. Release
> The U.K. drug-pricing watchdog NICE is likely to encounter resistance from pharma with its call for all clinical trial data to be published. Article | More
> With tech from the University of Miami, Biscayne Pharmaceuticals has grabbed a $1.5 million financing to research new growth hormone drugs. Release
@FierceMedDev: Medical device VC cash plunged 13% in 2012. Report | Follow @FierceMedDev
@DamianFierce: So, is $LIFE looking to sell itself? This PR is ominous. Release | Follow @DamianFierce
> Trauson's shares jump 41% on news of Stryker's $764M offer. Item
> GI Dynamics launches trial targeting FDA approval. Story
> FDA wants feedback on tighter hip-implant regs. News
Pharma News
@FiercePharma: Not as good for branded pharma, CHMP also OK'd generic versions of Forest's Namenda + Boehringer's Micardis. More | Follow @FiercePharma
@AlisonBFierce: Roche said U.S. regulators will allow it to begin selling the company's reserve stock of adult Tamiflu capsules. News | Follow @AlisonBFierce
@EricPFierce: Costco jumps into pharmacy benefits, bringing a new player to the table for drug companies to think about. Report | Follow @EricPFierce
> Pfizer's Bosulif set for greater sales with EMA approval. Article
> Pfizer sets share price for animal health spinoff. Report
> FTC says pay-to-delay getting worse; GpHA says nonsense. News
And Finally… Acorda Therapeutics ($ACOR) CEO Ron Cohen wants the U.S. to alter its tax code to cater to biotech investment. Forbes column